BioStock: BrainCool’s thrombectomy data presented at NeuroRad 2022

Earlier this year, BrainCool communicated safety and feasibility data from a clinical study on early brain cooling of 22 stroke patients treated with thrombectomy using the company’s products RhinoChill and BrainCool System. Last week, the EU-funded study Cottis 1 was presented at the scientific meeting NeuroRad 2022 in Germany after a three-month survival follow-up, the standard measure in stroke studies. According to BrainCool’s CEO Martin Waleij, the results are a strong signal that the technology is working, and the next step in the EU-funded project will now be a randomised pivotal clinical trial.

Read the full article about BrainCool at biostock.se:

https://www.biostock.se/en/2022/10/braincools-thrombectomy-data-presented-at-neurorad-2022/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/